| An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study TM Miller, A Pestronk, W David, J Rothstein, E Simpson, SH Appel, ... The Lancet Neurology 12 (5), 435-442, 2013 | 672 | 2013 |
| Genome-wide analyses identify KIF5A as a novel ALS gene A Nicolas, KP Kenna, AE Renton, N Ticozzi, F Faghri, R Chia, ... Neuron 97 (6), 1268-1283. e6, 2018 | 577 | 2018 |
| Systematic review of reversible cerebral vasoconstriction syndrome A Sattar, G Manousakis, MB Jensen Expert review of cardiovascular therapy 8 (10), 1417-1421, 2010 | 195 | 2010 |
| Neurological involvement of coronavirus disease 2019: a systematic review M Ghannam, Q Alshaer, M Al-Chalabi, L Zakarna, J Robertson, ... Journal of neurology 267, 3135-3153, 2020 | 180 | 2020 |
| Progressive external ophthalmoplegia C McClelland, G Manousakis, MS Lee Current neurology and neuroscience reports 16, 1-10, 2016 | 107 | 2016 |
| Multifocal radiculoneuropathy during ipilimumab treatment of melanoma G Manousakis, J Koch, RB Sommerville, A El‐Dokla, MB Harms, ... Muscle & nerve 48 (3), 440-444, 2013 | 71 | 2013 |
| Plasma exchange after initial intravenous immunoglobulin treatment in Guillain-Barré syndrome: critical reassessment of effectiveness and cost-efficiency M Oczko-Walker, G Manousakis, S Wang, JS Malter, AJ Waclawik Journal of clinical neuromuscular disease 12 (2), 55-61, 2010 | 62 | 2010 |
| Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study JF Howard, S Bresch, A Genge, C Hewamadduma, J Hinton, Y Hussain, ... The Lancet Neurology 22 (5), 395-406, 2023 | 61 | 2023 |
| The interface between stroke and infectious disease: infectious diseases leading to stroke and infections complicating stroke G Manousakis, MB Jensen, MR Chacon, JA Sattin, RL Levine Current neurology and neuroscience reports 9 (1), 28-34, 2009 | 60 | 2009 |
| A first presentation of multiple sclerosis with concurrent COVID-19 infection L Moore, M Ghannam, G Manousakis Eneurologicalsci 22, 100299, 2021 | 43 | 2021 |
| A phase I, randomised, first-in-human study of an antisense oligonucleotide directed against SOD1 delivered intrathecally in SOD1-familial ALS patients T Miller, A Pestronk, W David, J Rothstein, E Simpson, SH Appel, ... Lancet neurology 12 (5), 435, 2013 | 27 | 2013 |
| Neurochemical correlates of functional decline in amyotrophic lateral sclerosis I Cheong, DK Deelchand, LE Eberly, M Marjańska, G Manousakis, ... Journal of Neurology, Neurosurgery & Psychiatry 90 (3), 294-301, 2019 | 24 | 2019 |
| Genotype–phenotype correlations in valosin-containing protein disease: a retrospective muticentre study M Schiava, C Ikenaga, RN Villar-Quiles, M Caballero-Ávila, A Topf, ... Journal of Neurology, Neurosurgery & Psychiatry 93 (10), 1099-1111, 2022 | 22 | 2022 |
| Phase 2B randomized controlled trial of NP001 in amyotrophic lateral sclerosis: pre‐specified and post hoc analyses RG Miller, R Zhang, PM Bracci, A Azhir, R Barohn, R Bedlack, M Benatar, ... Muscle & nerve 66 (1), 39-49, 2022 | 21 | 2022 |
| The CINRG Becker natural history study: baseline characteristics PR Clemens, G Niizawa, J Feng, J Florence, AS DʼAlessandro, ... Muscle & nerve 62 (3), 369-376, 2020 | 17 | 2020 |
| Tract-specific analysis improves sensitivity of spinal cord diffusion MRI to cross-sectional and longitudinal changes in amyotrophic lateral sclerosis PK Pisharady, LE Eberly, I Cheong, G Manousakis, G Guliani, HB Clark, ... Communications biology 3 (1), 370, 2020 | 17 | 2020 |
| Cognitive outcome of cerebral fat embolism G Manousakis, DY Han, M Backonja Journal of Stroke and Cerebrovascular Diseases 21 (8), 906. e1-906. e3, 2012 | 17 | 2012 |
| Randomized phase 2 study of ACE‐083, a muscle‐promoting agent, in facioscapulohumeral muscular dystrophy JM Statland, C Campbell, U Desai, C Karam, J Díaz‐Manera, JT Guptill, ... Muscle & nerve 66 (1), 50-62, 2022 | 9 | 2022 |
| Case report: immune mediated necrotizing myopathy with IgG antibodies to 3-hydroxy-3-methylglutaryl-coenzyme a reductase (HMGCR) may present with acute systolic heart failure M Ghannam, G Manousakis Frontiers in Neurology 11, 571716, 2020 | 9 | 2020 |
| Results for a dose-escalation phase 2 study to evaluate ACE-083, a local muscle therapeutic, in patients with facioscapulohumeral muscular dystrophy J Statland, E Bravver, C Karam, L Elman, N Johnson, N Joyce Neuromuscular Disorders 28 (Supplement 2), S140, 2018 | 9 | 2018 |
